is not without its detractors. Some viewers on review forums express frustration with its pacing.
Many solid tumors exploit HPK1. Persistent antigen stimulation in the tumor microenvironment upregulates HPK1 activity, contributing to T cell dysfunction and exhaustion. By inhibiting HPK1, drugs like KBI-092 aim to lower the activation threshold of T cells, making them more resilient to suppressive signals and more effective at killing cancer cells. KBI-092
If this classification does not fit your needs, please provide more details. It could also relate to: Kansas Bureau of Investigation (KBI): is not without its detractors
: Often used in oncology to block signals that tell cancer cells to grow. KBI-092